APO-LEVOTHYROXINE 137 MCG — DIN 02550776
LEVOTHYROXINE SODIUM : 137 MCG · APOTEX INC · TABLET · wholesale supply in Canada
Health Canada status: MARKETED
What is APO-LEVOTHYROXINE?
APO-LEVOTHYROXINE 137 MCG contains LEVOTHYROXINE SODIUM : 137 MCG. It is listed in the Health Canada Drug Product Database under DIN 02550776, held by APOTEX INC, supplied as TABLET for ORAL administration. Health Canada currently lists it as marketed, status dated 17-Mar-2025. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is APO-LEVOTHYROXINE used for?
APO-LEVOTHYROXINE (levothyroxine sodium) is indicated as a replacement or supplemental therapy in patients of any age with primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) hypothyroidism of any etiology, in any state (including pregnancy) except transient hypothyroidism during the recovery phase of subacute thyroiditis. It is also indicated as an adjunct to surgery and radioactive iodine therapy in the management of thyrotropin-dependent well-differentiated papillary or follicular carcinoma of the thyroid.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
How much does Levothyroxine Sodium cost around the world?
Levothyroxine Sodium is listed on 4 of the national price registers Nexara ingests. Each country publishes on a different basis, so those figures are not comparable with one another — or with a Canadian wholesale price.
What a market publishes matters more than the number it publishes. Australia publishes a ex-manufacturer; Greece publishes a producer price (ex-factory); United Kingdom publishes a hospital. Comparing an ex-factory ceiling against a pharmacy public price tells you nothing about either, and comparing either against a Canadian landed cost tells you less.
| Market | Price basis published there | Brands | Packs listed | Range |
|---|---|---|---|---|
| United States | acquisition | 12 | 305 | USD███.██ |
| Greece | producer price (ex-factory) | 69 | 69 | EUR███.██ |
| Australia | ex-manufacturer | 9 | 37 | AUD███.██ |
| United Kingdom | hospital | 9 | 9 | GBP███.██ |
420 pack listings across 99 brand entries and 4 price bases, refreshed 08 Sep 2026. Ranges span every Levothyroxine Sodium pack in that market, so a high figure is usually a larger pack rather than the same product.
Canada publishes no comparable public list price. For a delivered Canadian price on a licensed account, verify your licence — it takes about a minute.
Is there a generic Levothyroxine Sodium in Canada, and who makes it?
Every market authorization holder with a Canadian DIN for this molecule, and how many of their listings Health Canada currently shows as marketed.
11 holders have a Canadian DIN containing Levothyroxine Sodium, across 109 DINs, of which 33 are currently marketed. Marketed count is the number that matters: an approval that is not marketed cannot be bought.
| Market authorization holder | DINs | Marketed | Brand names | Position |
|---|---|---|---|---|
| APOTEX INC | 12 | 12 | APO-LEVOTHYROXINE | Sourceable in Canada |
| BGP PHARMA ULC | 12 | 12 | SYNTHROID | Sourceable in Canada |
| ASPEN PHARMACARE CANADA INC. | 12 | 4 | ELTROXIN | Sourceable in Canada |
| FRESENIUS KABI CANADA LTD | 4 | 3 | LEVOTHYROXINE SODIUM FOR INJECTION, LEVOTHYROXINE SODIUM INJECTION | Sourceable in Canada |
| AVIR PHARMA INC. | 2 | 2 | LEVOTHYROXINE SODIUM FOR INJECTION | Sourceable in Canada |
| PHARMASCIENCE INC | 16 | 0 | LEVO-T 100MCG - TAB, LEVO-T 125MCG - TAB, LEVO-T 150MCG - TAB, LEVO-T 200MCG - TAB, LEVO-T 25MCG - TAB, +11 more | No marketed DIN |
| BOOTS PHARMACEUTICALS LTD. | 12 | 0 | SYNTHROID LIQ INJ 500MCG/VIAL USP, SYNTHROID TAB 100MCG USP, SYNTHROID TAB 112MCG USP, SYNTHROID TAB 125MCG USP, SYNTHROID TAB 150MCG USP, +7 more | No marketed DIN |
| EMD SERONO, A DIVISION OF EMD INC., CANADA | 12 | 0 | EUTHYROX | No marketed DIN |
| IBSA INSTITUT BIOCHIMIQUE SA | 12 | 0 | TIROCAP | No marketed DIN |
| TECHNILAB PHARMA INC. | 10 | 0 | LEVOTEC 100MCG TABLETS USP, LEVOTEC 112MCG TABLETS USP, LEVOTEC 125MCG TABLETS USP, LEVOTEC 150MCG TABLETS USP, LEVOTEC 175MCG TABLETS USP, +5 more | No marketed DIN |
| GLAXO CANADA INC | 5 | 0 | ELTROXIN 150 TAB, ELTROXIN TAB 100MCG, ELTROXIN TAB 200MCG, ELTROXIN TAB 300MCG, ELTROXIN TAB 50MCG | No marketed DIN |
Health Canada’s Drug Product Database does not flag which listing is the originator and which are subsequent-entry products, so Nexara does not label them here. Interchangeability is determined provincially, not federally — confirm for your province before a formulary switch. Nexara can confirm which of these is actually obtainable, and on what lead time, per order.
How is it supplied and stored?
Pack configuration, storage class and the handling constraints that drive cold-chain planning. One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced.
| Strength on the label | 137 MCG |
|---|---|
| Dosage form | TABLET |
| Route | ORAL |
| Pack configuration (monograph) | null |
| Storage | null |
Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation.
Substance and classification
| Active substance | Levothyroxine Sodium |
|---|---|
| ATC code | H03AA01 |
| Biosimilar biologic | No |
Health Canada record and identifiers
The regulatory facts straight from the Drug Product Database, plus every identifier form Nexara accepts on a purchase order. A DIN written without its leading zeros is the commonest reason an order line fails to match.
| DIN (8-digit, as used in ordering) | 02550776 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2550776 |
| Brand name | APO-LEVOTHYROXINE |
| Generic / active ingredient | LEVOTHYROXINE SODIUM : 137 MCG |
| Market authorization holder | APOTEX INC |
| Health Canada schedule | Prescription |
| ATC code | H03AA01 |
| ATC anatomical main group | H — Systemic hormonal preparations |
| ATC therapeutic subgroup | H03AA |
| Current status | MARKETED |
| Status date | 17-Mar-2025 |
| Status source | Live Health Canada DPD sync |
Verify on the primary sources
Is Levothyroxine Sodium in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by FRESENIUS KABI CANADA LTD, last seen 24 Apr 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Alternatives on every axis a buyer actually considers — the same molecule in another presentation, the same class, an adjacent class, or a fixed-dose combination. Every row is led by the marketed DIN count, because that is what can be bought this week.
1 · Same molecule, other Canadian presentations
33 of 109 Canadian DINs for this molecule are currently marketed. Marketed products are listed first.
| Product | Strength | Form | Holder | Health Canada status | DIN |
|---|---|---|---|---|---|
| APO-LEVOTHYROXINE | 150 MCG | TABLET | APOTEX INC | MARKETED | 02550784 |
| APO-LEVOTHYROXINE | 75 MCG | TABLET | APOTEX INC | MARKETED | 02550725 |
| APO-LEVOTHYROXINE | 112 MCG | TABLET | APOTEX INC | MARKETED | 02550741 |
| APO-LEVOTHYROXINE | 125 MCG | TABLET | APOTEX INC | MARKETED | 02550768 |
| APO-LEVOTHYROXINE | 300 MCG | TABLET | APOTEX INC | MARKETED | 02534703 |
| APO-LEVOTHYROXINE | 100 MCG | TABLET | APOTEX INC | MARKETED | 02534681 |
| APO-LEVOTHYROXINE | 50 MCG | TABLET | APOTEX INC | MARKETED | 02550717 |
| APO-LEVOTHYROXINE | 88 MCG | TABLET | APOTEX INC | MARKETED | 02550733 |
| APO-LEVOTHYROXINE | 25 MCG | TABLET | APOTEX INC | MARKETED | 02550709 |
| APO-LEVOTHYROXINE | 175 MCG | TABLET | APOTEX INC | MARKETED | 02550792 |
2 · Same class — other molecules in ATC H03AA
| Molecule | Canadian brands | DINs | Marketed | Sourceable |
|---|---|---|---|---|
| Levothyroxine Sodium | APO-LEVOTHYROXINE · ELTROXIN · ELTROXIN 150 TAB · ELTROXIN TAB 100MCG · +46 more | 109 | 33 | Yes |
| Liothyronine Sodium | AURO-LIOTHYRONINE · CYTOMEL · TEVA-LIOTHYRONINE | 6 | 6 | Yes |
| Thyroid Gland Preparations | ERFA THYROID | 3 | 0 | Not in Canada |
A molecule with zero marketed DINs cannot be sourced domestically, however many approvals it holds — if one of these sits on a formulary or in an older protocol, that is the line to check.
Not clinical advice. These tables describe what can be supplied in Canada, not what should be prescribed. Substitution within or across classes is a prescriber and pharmacist decision, and interchangeability is determined provincially.
What else is APO-LEVOTHYROXINE called?
The same molecule, Levothyroxine Sodium, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| Eltroxin | Latin | Australia |
| Eutroxsig | Latin | Australia |
| Levothox | Latin | Australia |
| Levothyroxine Lup | Latin | Australia |
| Levothyroxine Sandoz | Latin | Australia |
| LEVOXINE | Latin | Australia |
| Oroxine | Latin | Australia |
| Thyrox | Latin | Australia |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address. Patients and unlicensed buyers are routed to a partner pharmacy.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Why is there no price on this page?
Nexara quotes a delivered Canadian price per order, against a verified licence. Foreign list prices are published on incompatible bases and are not a guide to what any buyer can obtain here, so this page shows which markets list the molecule and on what basis, and nothing more.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.